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ABSTRACT 
Plasma homocysteine levels predict heart failure incidence in prospective epidemiological studies. 
We evaluated whether selective homocysteine lowering gene transfer beneficially affects cardiac 
remodelling and function in a model of pressure overload-induced cardiomyopathy induced by 
transverse aortic constriction (TAC). Female C57BL/6 low-density lipoprotein receptor (Ldlr
-/-
) 
cystathionine--synthase (Cbs+/-) mice were fed standard chow (control mice) or a folate-depleted, 
methionine-enriched diet to induce hyperhomocysteinemia (diet mice). Three weeks after 
initiation of this diet, mice were intravenously injected with 5 x 10
10
 viral particles of an E1E3E4-
deleted hepatocyte-specific adenoviral vector expressing Cbs (AdCBS), with the same dose of 
control vector, or with saline buffer. TAC or sham operation was performed two weeks later. 
AdCBS gene transfer resulted in 86.4% (p<0.001) and 84.6% (p<0.001) lower homocysteine 
levels in diet sham mice and diet TAC mice, respectively. Mortality rate was significantly 
reduced in diet AdCBS TAC mice compared to diet TAC mice during a follow-up period of 8 
weeks (hazard ratio for mortality 0.495, 95% CI 0.249 to 0.985). Left ventricular hypertrophy 
(p<0.01) and interstitial myocardial fibrosis (p<0.001) were strikingly lower in control TAC mice 
and diet AdCBS TAC mice compared to diet TAC mice. Diastolic function in diet AdCBS TAC 
mice was similar to that of control TAC mice and was significantly improved compared to diet 
TAC mice. AdCBS gene transfer potently reduced oxidative stress as evidenced by a reduction of 
plasma TBARS and a reduction of myocardial 3-nitrotyrosine-positive area (%). In conclusion, 
selective homocysteine lowering potently attenuates pressure overload-induced cardiomyopathy 
via reduced oxidative stress.  
 
KEYWORDS 
Heart failure, homocysteine, cardiomyopathy, transverse aortic constriction, gene transfer. 
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INTRODUCTION 
Clinical data support the hypothesis that plasma homocysteine levels modulate myocardial 
biology and function. Plasma homocysteine levels are directly related to left ventricular mass and 
wall thickness in women but not in men in the Framingham Heart Study participants that were 
free of heart failure and previous myocardial infarction[1]. Elevated homocysteine levels are 
associated with reduced regional left ventricular systolic function determined by tagged magnetic 
resonance imaging in asymptomatic subjects[2]. Furthermore, left ventricular diastolic function is 
significantly worse in hypertensive patients with elevated levels of homocysteine compared to 
hypertensive patients with normal homocysteine levels[3]. Finally, plasma homocysteine levels 
predict heart failure incidence in patients with or without prior myocardial infarction[4-6]. 
Notwithstanding the consistency of the results of these clinical studies, a causal role of 
homocysteine in myocardial biology and function cannot be proven since residual confounding in 
multivariable models may occur. 
The potential role of homocysteine on cardiac function is supported by in vitro and ex vivo 
experiments. In isolated cultured adult rat ventricular myocytes, exposure to homocysteine 
increases production of reactive oxygen species, impairs cardiomyocyte contractility in a 
concentration-dependent manner, and promotes apoptosis[7]. Cardiomyocytes isolated from 
hyperhomocysteinemic mice are characterized by impaired ex vivo contraction and relaxation[8].  
Mild hyperhomocysteinemia induced in rats via chronic methionine administration or in 
heterozygous cystathionine--synthase (Cbs) deficient mice induces cardiomyocyte hypertrophy 
and interstitial fibrosis[9,10]. However, an analysis of in vivo cardiac function has not been 
performed in these models. Recently, we demonstrated that selective homocysteine lowering gene 
transfer in female C57BL/6 low-density lipoprotein receptor (Ldlr)
-/-
 Cbs
+/-
 mice fed a folate-
depleted, methionine-enriched diet improves infarct healing, attenuates adverse ventricular 
remodelling, and significantly enhances diastolic function following permanent ligation of the left 
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anterior descending coronary artery[11]. However, since beneficial effects of selective 
homocysteine lowering gene therapy on cardiac function post-ligation of the left anterior 
descending coronary artery may be entirely dependent on improved infarct healing and reduced 
infarct expansion, direct effects of homocysteine levels on the ventricular wall cannot be proven 
in this model of myocardial infarction. 
Transverse aortic constriction (TAC) is a commonly used model of pressure overload-induced 
cardiac hypertrophy and heart failure[12]. TAC initially leads to compensatory hypertrophy of the 
heart, but over time, the response to chronic hemodynamic overload becomes maladaptive and 
results in cardiac dilatation and heart failure with reduced ejection fraction. The objective of the 
current study is to evaluate whether plasma homocysteine has direct effects on the myocardium 
by investigating the impact of selective homocysteine lowering gene transfer on the development 
of pressure overload-induced cardiomyopathy in mice. Specifically, we investigated the 
hypothesis that lower homocysteine levels inhibit the development of non-ischemic 
cardiomyopathy via reduced oxidative stress.  
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MATERIALS AND METHODS  
For detailed methodology, please see the Supplementary Materials and Methods in the Electronic 
Supplementary Material. 
Construction, generation, and production of E1E3E4-deleted adenoviral gene transfer vectors-
The construction of the E1E3E4-deleted adenoviral vector AdCBS, which induces hepatocyte-
specific expression of cystathionine--synthase (CBS), has been described previously[13]. This 
vector contains the 1.27 kb DC172 promoter[14], consisting of an 890 bp human 1-antitrypsin 
promoter and two copies of the 160 bp 1-microglobulin enhancer, upstream of the 5’ 
untranslated region of the human apo A-I gene that contains the first intron, the 1.7 kb cDNA 
sequence of murine Cbs, and 2 copies of the 774 bp hepatic control region-1. Hepatic 
overexpression of murine CBS after AdCBS gene transfer in C57BL/6 Ldlr
-/-
 Cbs
+/-
 mice has 
been previously confirmed by Western blot[11]. The E1E3E4-deleted control vector Adnull does 
not contain an expression cassette[15]. Large scale vector production was performed as described 
previously[15].  
In vivo experiments-All experimental procedures in animals were performed in accordance with 
protocols approved by the Institutional Animal Care and Research Advisory Committee of the 
Catholic University of Leuven (Approval number: P154/2013). Control female C57BL/6 Ldlr
-/-
 
Cbs
+/-
 mice[13] were fed standard chow (Sniff Spezialdiäten GMBH, Soest, Germany). Diet mice 
received a folate-depleted, methionine-enriched diet  (TD00205; 0.2 mg/kg folic acid, 4.1 g/kg L-
methionine; Harlan Teklad, Horst, The Netherlands) starting from the age of 12 weeks to induce 
hyperhomocysteinemia. Three weeks after initiation of this diet, tail vein injection was performed 
with 5 x 10
10
 adenoviral particles of AdCBS, with the same dose of the control vector Adnull, or 
with saline buffer. The equivalency of Adnull and saline injection with regard to different 
outcome measures has been demonstrated in several studies[16-18,11]. The experimental diet was 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 6 
maintained throughout the entire duration of the experiments. Taken together, control mice were 
compared with diet mice and diet AdCBS mice.  
To induce pressure overload, transverse aortic constriction (TAC) was performed two weeks after 
gene transfer or saline injection as previously described[12,19]. The sham procedure was identical 
except that no constriction on the aorta was applied. 
Biochemical endpoint analyses-A detailed description of these quantifications is included in the 
Supplementary Materials and Methods.  
In vivo hemodynamic measurements-Invasive hemodynamic measurements were performed 8 
weeks after TAC or after sham operation as described before[17]. A detailed description can be 
found in the Supplementary Materials and Methods.  
Histological and morphometric analysis-After hemodynamic analysis, mice were perfused via 
the abdominal aorta with phosphate-buffered saline (PBS) and hearts were arrested in diastole by 
CdCl (100 µl; 0.1 N), followed by perfusion fixation with 1% paraformaldehyde in phosphate 
buffered saline. After dissection, hearts were post-fixated overnight in 1% paraformaldehyde, 
embedded in paraffin, and 6 µm thick cross-sections at 130 µm spaced intervals were made 
extending from the apex to the basal part of the left ventricle. Left ventricle (LV) remodelling was 
assessed by morphometric analysis on mosaic images of Sirius red-stained heart cross-sections 
using Axiovision 4.6 software (Zeiss, Zaventem, Belgium). Whole LV area (mm
2
), LV cavity 
area (mm
2
), LV remote muscle area including the entire septum (mm
2
), anterior wall thickness, 
and septal wall thickness were analyzed. All geometric measurements were computed in a blinded 
fashion from representative tissue sections of 4 separate regions and the average value was used 
to represent that animal for statistical purposes.  
A detailed description of (immuno)histochemical analyses is included in the Supplementary 
Materials and Methods. 
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Statistical analysis-All data are expressed as means  standard error of the means (SEM). 
Detailed description of statistical analysis can be retrieved in the Supplementary Materials and 
Methods.  
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RESULTS 
AdCBS gene transfer selectively lowers homocysteine levels in diet
 
mice 
Plasma homocysteine levels were 15.5-fold (p<0.001) and 19.4-fold (p<0.001) higher in diet 
sham and diet TAC C57BL/6 Ldlr
-/-
 Cbs
+/- 
mice compared to respective control groups (Figure 1). 
AdCBS gene transfer resulted in 86.4% (p<0.001) and 84.6% (p<0.001) lower homocysteine 
levels in diet sham mice and diet TAC mice, respectively. No significant difference of plasma 
homocysteine levels was observed between control groups and diet AdCBS groups (Figure 1). As 
illustrated in Supplementary Table 1, there was no impact of the diet, of AdCBS gene transfer, or 
of the TAC procedure on plasma lipoprotein cholesterol levels.  
Selective homocysteine lowering gene transfer improves survival after TAC in diet mice 
Comparison of Kaplan-Meier survival curves (Figure 2) showed a higher mortality rate in diet 
TAC mice compared to TAC control mice (p=0.0519) (hazard ratio for mortality 1.97, 95% CI 
0.994 to 3.89). Mortality rate was significantly reduced in diet AdCBS TAC mice compared to 
diet TAC mice (p<0.05) (hazard ratio for mortality 0.495, 95% CI 0.249 to 0.985) (Figure 2). No 
significant difference in mortality rate was observed between control TAC mice and diet AdCBS 
TAC mice (Figure 2). Sham operation did not result in any mortality (data not shown). 
Cardiac hypertrophy is lower and interstitial fibrosis is reduced in diet AdCBS TAC mice 
compared to diet TAC mice 
No significant difference in heart weights (Figure 3A) or lung weights (Figure 3B) was observed 
between the different sham groups. The heart weight was 2.55-fold (p<0.0001) higher in diet 
TAC mice compared to diet sham mice (Figure 3A). Compared to diet TAC mice, cardiac 
hypertrophy was 25.3% (p<0.01) and 16.0% (p<0.05) lower in control TAC mice and diet 
AdCBS TAC mice, respectively. The lung weight was 2.07-fold (p<0.001) higher in diet TAC 
mice compared to diet sham mice (Figure 3B). Lung weight was 32.8% (p<0.05) and 15.5% 
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(p=NS) lower in control TAC mice and diet AdCBS TAC mice, respectively, than in diet TAC 
mice.  
Morphometric and histological parameters of the left ventricular myocardium 8 weeks after sham 
operation are shown in Table 1. No significant differences were observed between the three 
groups with the exception of a slight increase of interstitial fibrosis in diet sham mice and diet 
AdCBS sham mice compared to sham control mice. Morphometric and histological parameters of 
the left ventricular myocardium 8 weeks after TAC are illustrated in Table 2. In agreement with 
the heart weight data (Figure 3A), LV wall area, septal wall thickness, and anterior wall thickness 
were significantly lower in control TAC mice and diet AdCBS TAC mice compared to diet TAC 
mice (Table 2, Supplementary Figure 1). Cardiomyocyte hypertrophy was significantly more 
pronounced in the diet TAC mice compared to the two other groups (Table 2, Supplementary 
Figure 2). Capillary density and relative vascularity were 22.9% (p<0.05) and 24.4% (p=NS) 
higher, respectively, in diet AdCBS TAC mice compared to diet TAC mice (Table 2, 
Supplementary Figure 2). Interstitial fibrosis was strikingly lower in control TAC mice and diet 
AdCBS TAC mice compared to diet TAC mice (Table 2, Supplementary Figure 2). Apoptosis in 
the myocardium was evaluated using immunohistochemical quantification of cleaved caspase-3. 
Cleaved caspase-3 positive cells were undetectable in the myocardium of control sham mice and 
diet AdCBS sham mice whereas cleaved caspase-3 positive cells were infrequently observed in 
diet sham mice (Table 1). Compared to diet TAC mice, the number of cleaved caspase-3 positive 
cells was reduced by 36.0% (p<0.01) and 32.9% (p<0.01) in control TAC mice and diet AdCBS 
TAC mice, respectively (Table 2). 
Selective homocysteine lowering gene transfer improves diastolic function after TAC 
Hemodynamic parameters in the left ventricle and in the aorta 8 weeks after sham operation are 
summarized in Table 3. There was a 15.7% (p<0.01) decrease of the absolute value of the peak 
rate of isovolumetric relaxation (dP/dtmin) in diet sham mice compared to control sham mice. 
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Following TAC, diastolic function in diet AdCBS mice was similar compared to control mice and 
was significantly improved compared to diet mice as evidenced by the higher absolute value of 
dP/dtmin and a lower value of the time constant of left ventricular relaxation (Table 4). End-
diastolic pressure was significantly lower in control TAC mice and diet AdCBS TAC mice than 
in diet TAC mice (Table 4). 
 
Hyperhomocysteinemia reduces antioxidants and decreases antioxidant defense systems in 
plasma 
To quantify antioxidants and antioxidant defense systems, the concentration of glutathione (GSH) 
and cysteine and the activity of glutathione peroxidase and superoxide dismutase were determined 
in plasma (Supplementary Table 2 and Supplementary Table 3). The concentration of glutathione 
(GSH) and cysteine were significantly reduced in diet sham mice compared to control sham mice 
and diet sham AdCBS mice (Supplementary Table 2). Furthermore, glutathione peroxidase 
activity and superoxide dismutase activity were significantly lower in diet sham mice compared 
to the other sham groups (Supplementary Table 2). As shown in Supplementary Table 3, 
antioxidants and antioxidant defense systems were significantly decreased in diet TAC mice 
compared to control TAC mice and diet AdCBS TAC mice. 
 
AdCBS gene transfer reduces oxidative stress 
Reduction of oxidative stress may underlie the beneficial effects of selective homocysteine 
lowering gene transfer on cardiac hypertrophy, interstitial fibrosis, and diastolic function. 
Compared to diet sham mice, plasma TBARS were 32.5% (p<0.05) lower in both control sham 
mice and diet AdCBS sham mice (Figure 4A). TBARS were increased by 30.3% (p=0.0542), 
126% (p<0.01), and 63.4% (p<0.01) in control TAC mice, diet TAC mice, and diet AdCBS TAC 
mice, respectively, compared to respective sham groups. Furthermore, TBARS were significantly 
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(p<0.001) higher in the diet TAC mice compared to the two other TAC groups (Figure 4A). 
Plasma asymmetric dimethylarginine (ADMA) levels were 26.6% (p<0.05) and 27.4% (p<0.05) 
higher in control sham mice and in diet AdCBS sham mice, respectively, than in diet sham mice 
(Figure 4B). Compared to respective sham groups, a significant increase of ADMA occurred in 
all TAC groups but no significant difference was observed between TAC groups (Figure 4B). 
Representative myocardial sections immunostained for 3-nitrotyrosine staining are shown in 
Figure 4C. Compared to respective sham groups, 3-nitrotyrosine-positive area (%) was increased 
4.65-fold (p<0.0001), 3.78-fold (p<0.001), and 2.69-fold (p<0.0001) in control TAC mice, diet 
TAC mice, and diet AdCBS TAC mice, respectively (Figure 4D). The 3-nitrotyrosine-positive 
area was 54.7% (p<0.01) and 38.6% (p<0.05) lower in control TAC mice and in diet AdCBS 
TAC mice, respectively, than in diet TAC mice. Taken together, selective homocysteine lowering 
gene transfer reduces myocardial oxidative stress.   
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DISCUSSION 
The main findings of the current study are that 1) selective homocysteine lowering gene therapy 
in a murine model of hyperhomocysteinemia significantly reduces mortality after TAC; 2) lower 
plasma homocysteine levels result in reduced cardiac hypertrophy, decreased interstitial fibrosis, 
and improved diastolic function after TAC compared to hyperhomocysteinemic mice; 3) lower 
homocysteine levels result in significantly improved antioxidant defense systems both in sham 
mice and in TAC mice; 4) lower homocysteine plasma levels reduce oxidative stress in both sham 
mice and in TAC mice as evidenced by a reduction of plasma TBARS and myocardial 3-
nitrotyrosine levels; 5) apoptosis in the myocardium is reduced in control TAC mice and diet 
AdCBS TAC mice compared to diet TAC mice.  
Most studies on the effect of homocysteine on biochemical, biological, and medical end-points 
depend on dietary manipulations that may have effects independent of homocysteine levels. An 
important strength of the current study is that the decrease of homocysteine levels in mice on the 
folate-depleted, methionine-enriched diet was induced by selective homocysteine lowering gene 
transfer. Therefore, dietary effects unrelated to homocysteine lowering cannot have an impact on 
the end-points in our study. Most but not all parameters were very similar in control TAC mice 
and in diet AdCBS TAC mice indicating that in general the impact of hyperhomocysteinemia 
overrides any effect resulting from homocysteine-unrelated differences between standard chow 
and the folate-depleted, methionine-enriched diet. 
Lower homocysteine levels were associated with lower lung weights at 8 weeks after TAC, which 
is indicative of decreased congestive heart failure. Furthermore, mortality in diet AdCBS TAC 
mice was significantly reduced compared to diet TAC mice, which predominantly reflects 
enhanced survival in the first four weeks after TAC. Early mortality after TAC may be caused by 
acute heart failure or by lethal arrhythmias[20]. 
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Lower plasma homocysteine levels resulted in reduced cardiac hypertrophy after TAC. According 
to the classic wall stress-hypothesis of Grosmann[21], pressure overload induces myocytes to 
grow in width until wall thickness has increased sufficiently to normalize systolic wall stress. In 
this concentric hypertrophy, the fibers get thicker because sarcomeres are laid down in 
parallel[22]. However, hypertrophy is also influenced by load-independent factors as 
demonstrated by the effect of genetic background[23] and as illustrated by observations in many 
transgenic models[24]. Notably, these studies[23,24] highlight that there is no direct relationship 
between the degree of cardiac hypertrophy and cardiac function. In a mouse model with 
transgenic inactivation of Gq, hypertrophy from pressure loading was less than predicted and wall 
stress was not normalized[25]. Contractility in these transgenic mice was better than in wild-type 
mice with more hypertrophy and normalization of wall stress. On the other hand, dual specificity 
mitogen-activated protein kinase kinase 1 (MEK1) transgenic mice demonstrated concentric 
hypertrophy without signs of cardiomyopathy or lethality up to 12 months of age[26]. These 
MEK1 transgenic mice showed a dramatic increase in cardiac function as quantified by 
echocardiography and as measured in isolated working heart preparations[26]. Here, we 
demonstrate that reduced cardiac hypertrophy following lowering of plasma homocysteine levels 
is associated with improved diastolic function and a trend for an improvement of systolic function. 
The relation between cardiac hypertrophy and cardiac function can also be analyzed from a 
clinical perspective. Left ventricular hypertrophy has an important prognostic value in patients. 
Hypertensive patients with concentric left ventricular hypertrophy have the highest incidence of 
cardiovascular events including death[27]. In patients with severe aortic stenosis, the degree of 
left ventricular hypertrophy independently predicts heart failure regardless of the degree of flow 
restriction imposed by the valve pathology[28]. Taken together, less pronounced left ventricular 
hypertrophy as observed following homocysteine lowering may be beneficial and may contribute 
to the improved cardiac function. In this regard, homocysteine levels in patients correlate with 
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brain natriuretic peptide[29] and the N-terminal of the prohormone brain natriuretic peptide[30], 
biomarkers of chronic heart failure. 
Pressure overload resulted in oxidative stress in all three TAC groups as evidenced by elevated 
plasma TBARS and 3-nitrotyrosine immunostaining. Oxidative stress refers to situations 
characterized by an imbalance between the production of reactive oxygen species and antioxidant 
defenses leading to oxidative modification of numerous biological substrates[31]. A chronic 
increase in reactive oxygen species plays a critical role in the development and progression of 
heart failure. Markers of oxidative stress are increased in patients with heart failure and correlate 
with the severity of cardiac dysfunction[32]. Reactive oxygen species can induce DNA damage, 
protein damage, and disrupt cell membranes. They may contribute to cardiomyocyte hypertrophy 
and lead to cardiomyocyte apoptosis. Reactive oxygen species can be produced through electron 
leakage from the mitochondria during oxidative phosphorylation. Alternatively, they are 
generated by several enzymes including nicotinamide adenine dinucleotide phosphate (NADPH)-
oxidase, xanthine oxidase, and nitric oxide synthase[33].  
Hyperhomocysteinemia augmented oxidative stress in TAC mice. Antioxidants (glutathione, 
cysteine) and antioxidant defense systems (glutathione peroxidase, superoxide dismutase) were 
significantly lower in hyperhomocysteinemic mice. CBS converts homocysteine to cystathionine. 
The increase of cysteine and glutathione following AdCBS gene transfer reflects increased 
substrate availability of metabolic pathways downstream of cystathionine. Handy et al.[34] 
previously demonstrated that homocysteine decreases glutathione peroxidase  activity by altering 
the specific translational mechanism essential for the synthesis of this selenocysteine-containing 
protein. Superoxide dismutase protein levels in the heart were reduced in a dog model[35] and in 
a rat model of chronic hyperhomocysteinemia[36]. Production of reactive oxygen species is 
increased by hyperhomocysteinemia. Auto-oxidation of homocysteine generates reactive oxygen 
species including superoxide, hydrogen peroxide, and hydroxyl radicals, and also directly 
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contributes to the depletion of nitric oxide via formation of peroxynitrite (ONOO
-
)[37,38]. In 
addition, hyperhomocysteinemia has been shown to induce NADPH-oxidase 2 (Nox2) [35] and 
Nox 4 in cardiomyocytes[39]. Furthermore, hyperhomocysteinemia promotes expression of 
inducible NO synthase (iNOS), further increasing superoxide radical formation[40]. In isolated 
cultured adult rat ventricular myocytes, exposure to homocysteine for 24 hours impaired 
cardiomyocyte contractility in a concentration-dependent manner and promoted apoptosis[7]. 
These effects were associated with activation of p38 mitogen-activated protein kinase and 
increased production of reactive oxygen species. Inhibition of p38 mitogen-activated protein 
kinase prevented all of the effects of homocysteine[7]. Furthermore, oxidative stress activates 
Ca
2+
-calmodulin kinase II. Under physiological conditions, this enzyme couples increases in 
intracellular Ca
2+
 to activation of ion channels by phosphorylation of a large and diverse set of 
effector targets[41]. As a result of oxidative stress, Ca2
+
-calmodulin kinase II activity is sustained, 
independent of Ca
2+
 and calmodulin amounts, which may induce cardiac arrhythmias[42]. This 
may contribute to increased mortality in diet TAC mice. This enzyme also provides a link 
between increased oxidative stress and increased apoptosis in diet TAC mice since knockdown of 
Ca
2+
-calmodulin kinase II in cardiac myocytes reduces apoptosis[42]. Oxidative stress may also 
contribute to increased interstitial fibrosis in diet TAC mice. Exposure of cardiac fibroblasts to 
superoxide anion enhances the production of transforming growth factor-β1 (TGF-β1)[43,44], 
which is a potent fibrogenic cytokine. Recently, up-regulation of Nox4 in the myocardium has 
been directly linked to increased interstitial fibrosis[45]. 
Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide 
(NO) synthase (NOS). ADMA is produced from the proteolysis of proteins that contain 
dimethylated arginine residues. ADMA levels were quite surprisingly lower in diet sham mice 
compared to the two sham groups with lower homocysteine levels. This observation may be the 
result of a large decrease in the hepatic methylation capacity (low S-adenosylmethionine-to-S-
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adenosylhomocysteine ratio) induced by the high-methionine low-folate diet in Cbs
+/-
 mice [46]. 
ADMA levels were increased in all three TAC groups compared to respective sham groups. 
These increments reflect the increased oxidative stress induced by TAC. Indeed, increased 
oxidative stress results in downregulation of dimethylarginine dimethylaminohydrolase[47-49]. 
Since dimethylarginine dimethylaminohydrolase hydrolyzes ADMA to citrulline and 
dimethylamine, reduced activity of this enzyme results in increased ADMA levels. However, in 
light of similar ADMA levels in the three TAC groups, our data do not indicate that ADMA 
levels contribute significantly to the more pronounced deterioration of cardiac function in diet 
TAC mice compared to the two TAC groups with low homocysteine levels. 
In conclusion, selective homocysteine lowering gene therapy in a murine model of 
hyperhomocysteinemia significantly reduces mortality, attenuates cardiac hypertrophy, decreases 
interstitial fibrosis, reduces apoptosis, and enhances diastolic function after TAC. These 
beneficial effects are likely closely linked to a profound reduction of oxidative stress secondary to 
the decrease of homocysteine levels.   
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LEGENDS TO THE FIGURES 
 
Figure 1. Plasma homocysteine levels in control, diet, and diet AdCBS mice. Sham mice and 
TAC mice are indicated by open bars and closed bars, respectively. Plasma samples were 
obtained at day 56 after sham operation or TAC. 
Figure 2. Kaplan-Meier survival curves after TAC. Control mice, diet mice, and diet AdCBS 
mice are indicated by black lines, red lines, and blue lines respectively. Survival curves were 
compared by log-rank test. 
Figure 3. Heart weights (panel A) and lung weights (panel B) in control, diet, and diet 
AdCBS mice. Sham mice and TAC mice are indicated by open bars and closed bars, respectively. 
Data reflect wet weights at day 56 after sham operation or TAC. 
Figure 4. Quantification of oxidative stress in sham mice and in TAC mice. Sham mice and 
TAC mice are indicated by open bars and closed bars, respectively. (A) Plasma TBARS 
expressed as plasma malondialdehyde equivalents. (B) Plasma asymmetric dimethylarginine 
levels. (C) Representative photomicrographs showing myocardial sections stained for 3-
nitrotyrosine. Scale bar represents 100 µm. (D) Percentage of 3-nitrotyrosine-positive area in the 
myocardium. 
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Table 1. Morphometric and histological parameters of the left ventricular myocardium 8 weeks after sham operation 
in female C57BL/6 Ldlr-/- Cbs+/- mice. 
Control mice were fed standard chow. The Diet (TD00205) is a folate-depleted, methionine-enriched diet.  
Data are expressed as means ± SEM. °: p<0.05; °°:p<0.01 versus Control sham. *:p<0.05 versus diet sham. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control sham  Diet sham Diet sham AdCBS 
Number of mice  12 17 24 
    
LV wall area (mm
2
)  8.89  0.30  9.07  0.30 8.95  0.11 
Septal wall thickness (µm)  1100  30  1110  30 1090  20 
Anterior wall thickness (µm)  1140  30  1130  30 1120  10 
    
Cardiomyocyte cross-sectional area (µm
2
) 215  12 184  8 186  6 
Cardiomyocyte density (number/mm
2
) 5110  200 5000  220 5320  160 
Capillary density (number/mm
2
) 6760  250 6320  170 6610  150 
Relative vascularity (µm
-2
) 0.00634  0.00031 0.00705  0.00023 0.00684  0.00020 
    
Interstitial fibrosis (%) 2.69  0.20 4.01  1.3°° 4.07  0.44° 
Perivascular fibrosis (ratio) 0.469  0.017 0.502  0.026 0.489  0.020 
    
Cleaved caspase 3 positive cells 
(number/mm
2
) 
0.00  0.01 2.09  1.33° 0.00  0.01* 
Table 1
 
Table 2. Morphometric and histological parameters of the left ventricular myocardium 8 weeks after TAC in female 
C57BL/6 Ldlr-/- Cbs+/- mice. 
Control mice were fed standard chow. The diet (TD00205) is a folate-depleted, methionine-enriched diet.  
Data are expressed as means ± SEM. °: p<0.05; °°:p<0.01; °°°:p<0.001 versus Control TAC. *:p<0.05; **:p<0.01; ***:p<0.001 
versus Diet TAC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control TAC Diet TAC Diet TAC AdCBS 
Number of mice  17 13 23 
    
LV wall area (mm
2
)  11.1  0.4  13.8  0.3°°° 12.3  0.4* 
Septal wall thickness (µm)  1280  30  1460  30°°° 1340  30** 
Anterior wall thickness (µm)  1340  30  1510  40°° 1320  30*** 
    
Cardiomyocyte cross-sectional area (µm
2
) 417  25 503  18° 420  25* 
Cardiomyocyte density (number/mm
2
) 3140  140 2500  100° 3210  210* 
Capillary density (number/mm
2
) 4560  190 4360  230 5360  280* 
Relative vascularity (µm
-2
) 0.00372  0.00024 0.00353  0.00019 0.00439  0.00027 
    
Interstitial fibrosis (%) 11.3  0.6 17.1  1.3° 9.21  0.89*** 
Perivascular fibrosis (ratio) 0.567  0.040 0.727  0.042° 0.529  0.020** 
    
Cleaved caspase 3 positive cells 
(number/mm
2
) 
15.8  1.5 24.7  2.0°° 16.6  1.0** 
Table 2
  
Table 3. Hemodynamic parameters in the left ventricle and in the aorta 8 weeks after sham operation in female C57BL/6 
Ldlr-/- Cbs+/- mice. 
 
 
Control mice were fed standard chow. The diet (TD00205) is a folate-depleted, methionine-enriched diet. Hemodynamic analysis 
was performed at the age of 25 weeks. Data are expressed as means ± SEM. °°:p<0.01 versus Control sham. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control sham Diet sham Diet sham AdCBS 
Number of mice  8 17 20 
LEFT VENTRICLE    
Peak systolic pressure (mm Hg)  103  3  99.1  1.4 99.4  2.3 
End-diastolic pressure (mm Hg)  3.07  0.45  1.69  0.49 1.69  0.36 
dP/dt max (mm Hg/ms)  13.6  0.8  11.6  0.6 11.9  0.4 
dP/dt min (mm Hg/ms) -11.4  0.5 -9.61  0.36°° -10.1  0.2 
Tau (ms) 4.46  0.19 4.83  0.19 4.83  0.12 
Heart rate (bpm) 598  18 611  10 571  11 
AORTA    
Mean pressure (mm Hg) 97.7  2.6 101  5 98.7  3.3 
Peak systolic pressure (mm Hg) 101  2 98.7  1.7 99.3  2.9 
Peak diastolic pressure (mm Hg) 64.9  3.4 69.6  2.9 67.6  4.0 
Table 3
  
Table 4. Hemodynamic parameters in the left ventricle and in the aorta 8 weeks after TAC in female C57BL/6 Ldlr-/- 
Cbs+/- mice. 
 
 
Control mice were fed standard chow. The diet (TD00205) is a folate-depleted, methionine-enriched diet. Hemodynamic analysis 
was performed at the age of 25 weeks. Data are expressed as means ± SEM. °:p<0.05; °°:p<0.01; °°°:p<0.001 versus Control 
TAC. *:p<0.05; **:p<0.01 versus Diet TAC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control TAC Diet TAC  Diet TAC AdCBS 
Number of mice  14 10 12 
LEFT VENTRICLE    
Peak systolic pressure (mm Hg)  162  6  159  8 164  4 
End-diastolic pressure (mm Hg)  1.88  0.55  6.26  0.80°°° 3.77  0.37** 
dP/dtmax (mm Hg/ms)  9.48  0.43  8.55  0.71 9.55  0.36 
dP/dtmin (mm Hg/ms) -9.25  0.58  -7.78  0.41° -9.02  0.25* 
Tau (ms) 5.72  0.22 7.07  0.30°° 5.91  0.24* 
Heart rate (bpm) 576  21 580  31 585  15 
AORTA    
Mean pressure (mm Hg) 97.7  2.6 101  5 98.2  3.8 
Peak systolic pressure (mm Hg) 159  5 157  8 163  5 
Peak diastolic pressure (mm Hg) 59.5  3.5 67.2  4.7 58.6  2.9 
Table 4
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